ClinicalTrials.Veeva

Menu
C

CTI Clinical Research Center | Cincinnati, OH

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3841136
Elagolix
Dihydroergotamine
Tirzepatide
Daridorexant
Atogepant
AD036
JZP-110
LY3298176
LY3305677

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 89 total trials

A Clinical Trial in Healthy Volunteers and Volunteers with Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination with an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

This exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is...

Enrolling
Genital Herpes Simplex Type 2
Other: Placebo
Biological: BNT163

Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior...

Enrolling
Overweight or Obesity
OSA
Drug: Placebo
Drug: Orforglipron

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3305677
Drug: LY3549492

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep (K-304) Dose level 3

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety...

Active, not recruiting
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3305677

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Active, not recruiting
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3841136

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant i...

Enrolling
Prader-Willi Syndrome
Other: Placebo tablet
Drug: Pitolisant tablet

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than t...

Active, not recruiting
Obesity
Drug: Mibavademab-Placebo
Drug: Tirzepatide-Placebo

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2...

Enrolling
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: COMIRNATY®

This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic...

Active, not recruiting
Idiopathic Hypersomnia
Narcolepsy
Drug: JZP258 (XYWAV)

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3549492

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune s...

Active, not recruiting
Shingles
Human
Biological: Selected Vaccine Candidate group (Dose level, Schedule)
Biological: Shingrix - SSB

This BARDA-sponsored, randomized, double-blind, phase 2 study is designed to assess safety and immunogenicity of A/H5 inactivated monovalent influenz...

Active, not recruiting
Influenza
Biological: 3.75 µg H5N8 antigen plus full dose AS03A
Biological: 7.5 µg H5N8 antigen plus half dose AS03A
Locations recently updated

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

Trial sponsors

Pfizer logo
Lilly logo
Apnimed logo
Moderna logo
AbbVie logo
Allergan logo
BioNTech logo
Idorsia Pharmaceuticals logo
Jazz Pharmaceuticals logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems